Phase II Randomized, Parallel-Group Trial on PTK-ZK [vatalanib] With or Without DTIC [dacarbazine] in Patients With Non-Resectable Metastatic Malignant Melanoma.
Phase of Trial: Phase I/II
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Vatalanib (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 11 Jan 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 26 Feb 2008 New trial record.